Launch Update: CNSide® Diagnostic Now Commercially Available in Texas

On July 31, 2025, Plus Therapeutics announced that its wholly-owned subsidiary, CNSide Diagnostics, LLC, is launching the CNSide® cerebrospinal fluid (CSF) assay platform in Texas starting August 2025. The initial rollout will prioritize NCI-Designated Cancer Centers and leading private healthcare systems in the state (Plus Therapeutics, Stock Titan, Yahoo Finance).

This commercial introduction follows extensive preparation, including infrastructure build-out and licensing, and sets the stage for broader regional coverage over the following 12 months (Plus Therapeutics, GlobeNewswire).

Why This Launch Matters

• Targeting major cancer institutions — The rollout will first focus on facilities best positioned to serve patients with leptomeningeal metastases (Stock Titan, Plus Therapeutics).
• Clinically validated performance — CNSide demonstrates 92% sensitivity and 95% specificity, based on over 11,000 tests performed at more than 200 U.S. cancer institutions since 2020 (Investing.com, MedPath, GuruFocus).
• Meaningful revenue outlook — Management anticipates that CNSide will begin contributing significant revenue in fiscal year 2026, supporting its growth trajectory (Investing.com, MedPath, Stock Titan).

#CNSideDiagnostics #CNSCancer #MedicalDiagnostics #HealthcareInnovation #PlusTherapeutics #LeptomeningealMetastases #CancerDiagnostics